Ecog 3200 trial

Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Last Update Posted : May 19, Study Description. Detailed Description:. Compare the methylation results to clinicopathologic and molecular findings and survival.

Outcome Measures. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

This numbering scale is one way to define the population of patients to be studied in the trial, so that it can be uniformly reproduced among physicians who enroll patients. It circulates in the public domain and is therefore available for public use.

It is displayed below both for future reference and to spur further standardization among researchers who design and evaluate cancer clinical research. Comis, MD, Group Chair. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. Fernandez, MD , Hugo F.

Fernandez, MD. Hillard M. Lazarus , Hillard M. Jacob M. Rowe, MD , Jacob M. Rowe, MD. Martin S. Tallman, MD , Martin S. Tallman, MD. Elisabeth M. Paietta, PhD , Elisabeth M. Paietta, PhD. Mark Litzow , Mark Litzow. Jay P. Patel , Jay P. Ross L. Levine, MD , Ross L. Levine, MD. Selina M. Luger, MD Selina M. Luger, MD. Blood 21 : Cite Icon Cite.